RAMPY NORTHRUP LLC for JOHNSON & JOHNSON SERVICES, INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5030/S.2706, DIVERSE Trials Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHEN NORTHRUP | — |
| STACEY RAMPY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.